[Article] Why Antimicrobial Resistance is a Silent Pandemic
“The pandemic has highlighted the fragility of the antibiotic pipeline”
A global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist. If there’s one silver lining of the COVID-19 pandemic, it is that it has increased public awareness of AMR and incited a new sense of urgency to develop effective agents against these pathogens.
You may also be interested in:
Supporting Antiviral, Antibacterial, Antifungal and Vaccine Clinical Research
Achieve quality results, meet deadlines, and maximize efficiencies by partnering with a full-service CRO that excels in designing and executing clinical research in antivirals, antibacterials, antifungals and vaccines. Extensive experience gives our medical, regulatory, and operational staff a thorough understanding of the complexities of ID trials from the perspectives of all the stakeholders involved in developing treatments for new and re-emerging infectious diseases.